Bruker Corp Liquidation Value

BRKR Laboratory Instruments

Cash & Equivalents

$133.40M
As of 2026-03-31
Current Price: N/A

Key Metrics

Cash Liquidation Value

Cash minus Total Obligations
Cash: $133.40M
Total Obligations: -$3.02B
$-2.88B
Per share: $-18.95
Period: 2026-03-31
incomplete 2 components missing — treated as $0 in formula. Why?
  • Finance Lease Liability: not reported in this period (annual-only)
  • Operating Lease Liability: not reported in this period (annual-only)

Liquid Liquidation Value

Cash + AR minus Total Obligations
Cash: $133.40M
AR: $542.70M
Total Obligations: -$3.02B
$-2.34B
Per share: $-15.38
Period: 2026-03-31
incomplete 2 components missing — treated as $0 in formula. Why?
  • Finance Lease Liability: not reported in this period (annual-only)
  • Operating Lease Liability: not reported in this period (annual-only)

Operating Liquidation Value

Cash + AR + Inventory minus Total Obligations
Cash: $133.40M
AR: $542.70M
Inventory: $1.12B
Total Obligations: -$3.02B
$-1.22B
Per share: $-8.02
Period: 2026-03-31
incomplete 2 components missing — treated as $0 in formula. Why?
  • Finance Lease Liability: not reported in this period (annual-only)
  • Operating Lease Liability: not reported in this period (annual-only)

Build your own liquidation scenario

Adjust asset discounts and liability assumptions to see how assumptions affect the numbers.

Open Calculator →

Liquidation Ladder

MetricTotalPer Share
Cash Liquidation Value$-2.88B$-18.95
Liquid Liquidation Value$-2.34B$-15.38
Operating Liquidation Value$-1.22B$-8.02

Key Components (as of 2026-03-31)

Data as of 2026-03-31 from 10-Q filed 2026-05-07. View on SEC EDGAR →

Cash & Equivalents$133.40M
Accounts Receivable$542.70M
Inventory$1.12B
Current Liabilities$1.36B
Long-term Debt (?)$1.66B
Op. Lease Liability (?)N/A
Finance Lease (?)N/A
Shares Outstanding152.2M

Explore all 166 XBRL tags and build your own scenario → Open Calculator

Historical

PeriodCashARInventoryAPCurr LiabLT DebtOp LeaseFin Lease
2026-03-31$133.40M$542.70M$1.12B$269.10M$1.36B$1.66BN/AN/A
2025-12-31$298.80M$544.90M$1.09B$215.90M$1.28B$1.85B$138.60M$13.80M
2025-09-30$293.10M$550.90M$1.20B$184.40M$1.27B$1.98BN/AN/A
2025-06-30$92.00M$522.60M$1.22B$243.00M$1.35B$2.38BN/AN/A
2025-03-31$184.20M$537.80M$1.12B$244.60M$1.34B$2.08BN/AN/A

Comments

SEC Filings

PeriodFormFiledLink
2026-03-31 10-Q 2026-05-07 View
2025-12-31 10-K 2026-02-27 View
2025-09-30 10-Q 2025-11-05 View
2025-06-30 10-Q 2025-08-06 View
2025-03-31 10-Q 2025-05-07 View
2024-12-31 10-K 2025-03-03 View
2024-09-30 10-Q 2024-11-07 View
2024-06-30 10-Q 2024-08-09 View

AI Insights

AI Insight·Generated 2026-05-09

Bruker Corp (BRKR) carries a deeply negative liquidation value as of March 31, 2026, consistent with its prior-period posture. MFFAIS pegs the cash liquidation value at -$2.88B, liquid liquidation value at -$2.34B, and operating liquidation value at -$1.22B. The asset base is dominated by goodwill ($1.57B) and finite-lived intangibles net ($902M), totaling $2.48B in intangible assets against a $6.13B total asset base — both haircut to zero under the liquidation lens. PP&E net of $720M recovers at 50-70%, contributing roughly $360-504M. Inventory at $1.12B (including $120M demo inventory and $72M in-transit) recovers at roughly 60%, or ~$673M. AR net of $543M recovers at 90-95%, or ~$488-516M. Cash of $133M recovers 100%. The liability stack is substantial: total long-term debt $1.67B carried at face, current liabilities $1.36B, non-current other liabilities $610M, and deferred/contract liabilities of $586M that do not extinguish in liquidation. Additionally, the Series A Mandatory Convertible Preferred Stock carries a $694M aggregate liquidation preference ($250/share on 2.76M shares), which sits senior to common equity and further erodes common equity recovery. The preferred dividend obligation ($10.9M per quarter) adds ongoing cash drag. During Q1 2026, BRKR repaid $181.3M of the 2024 term loan in full, reducing outstanding debt from prior levels, but total debt remains $1.67B. The company disclosed $2.71B in remaining performance obligations — relevant context for deferred revenue liability magnitude. Key asset-quality concerns include $12.9M in long-lived asset impairments related to BSI NANO restructuring (Note 10), continued elevated restructuring charges of $17.8M, and pending IEEPA tariff refund claims (material if approved but not recognized as receivable as of period end — filing discloses in MD&A but does not separately XBRL-tag any refund receivable). The filing discusses long-lived asset impairment charges and restructuring in MD&A but the specific segment-level asset write-downs for BSI NANO are not separately XBRL-tagged beyond ImpairmentOfLongLivedAssetsHeldForUse.

Flags

Loading flags...

AI Insight Discussion

Loading...

Community Notes

Loading notes...

Questions

Loading questions...